zaleplon has been researched along with Mental Disorders in 6 studies
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam
zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this work is to develop self-nano emulsifying drug delivery system (SNEDDS) to enhance the oral bioavailability of zaleplon (Zal) as a poorly water-soluble drug." | 2.90 | Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients. ( Eassa, HA; Elaidy, AM; Khalifa, MKA; Salem, HA; Shawky, SM, 2019) |
| "Insomnia is a cardinal symptom for many psychiatric disorders, especially depressive disorders." | 2.41 | A psychiatric perspective on insomnia. ( McCall, WV, 2001) |
| "In particular, patients with chronic insomnia have higher rates of psychiatric and medical illnesses, and insomnia is an important risk factor in the development of depression." | 2.41 | Consequences of insomnia and its therapies. ( Benca, RM, 2001) |
| "Comorbid psychiatric illness was diagnosed in 67 patients (39." | 1.46 | Benzodiazepine and "Z-Drug" Dependence: Data From a Tertiary Care Center. ( Benegal, V; Bokka, S; Chand, P; Kandasamy, A; Murthy, P; Shukla, L; Shukla, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khalifa, MKA | 1 |
| Salem, HA | 1 |
| Shawky, SM | 1 |
| Eassa, HA | 1 |
| Elaidy, AM | 1 |
| Shukla, L | 1 |
| Bokka, S | 1 |
| Shukla, T | 1 |
| Kandasamy, A | 1 |
| Chand, P | 1 |
| Benegal, V | 1 |
| Murthy, P | 1 |
| Schwartz, T | 1 |
| Nihalani, N | 1 |
| Virk, S | 1 |
| Jindal, S | 1 |
| Costello, A | 1 |
| Muldoon, R | 1 |
| Azhar, N | 1 |
| Hussein, J | 1 |
| Tirmazi, S | 1 |
| Kassam, A | 1 |
| Carter, B | 1 |
| Patten, SB | 1 |
| McCall, WV | 1 |
| Benca, RM | 1 |
2 reviews available for zaleplon and Mental Disorders
| Article | Year |
|---|---|
A psychiatric perspective on insomnia.
Topics: Acetamides; Benzodiazepines; Comorbidity; Depressive Disorder; Diagnosis, Differential; GABA-A Recep | 2001 |
Consequences of insomnia and its therapies.
Topics: Acetamides; Circadian Rhythm; Comorbidity; Half-Life; Health Status Indicators; Humans; Hypnotics an | 2001 |
2 trials available for zaleplon and Mental Disorders
| Article | Year |
|---|---|
Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients.
Topics: Acetamides; Administration, Oral; Adult; Biological Availability; Cross-Sectional Studies; Drug Carr | 2019 |
"A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia".
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Drug Monitoring; Female; Humans; Hypnotic | 2004 |
2 other studies available for zaleplon and Mental Disorders
| Article | Year |
|---|---|
Benzodiazepine and "Z-Drug" Dependence: Data From a Tertiary Care Center.
Topics: Acetamides; Adult; Azabicyclo Compounds; Bacterial Proteins; Benzodiazepines; Female; Humans; Hypnot | 2017 |
Sedative hypnotic use in Alberta.
Topics: Acetamides; Adolescent; Adult; Anxiety Disorders; Azabicyclo Compounds; Canada; Catchment Area, Heal | 2006 |